Depression and neurological disorders

Current Opinion in Psychiatry

Volumn 19, Issue 1, 2006, Pages 14-18

  Benedetti, Francesco ^a,b   Bernasconi, Alessandro ^a   Pontiggia, Adriana ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Brain imaging; Depression; Neurological disorder

Indexed keywords

CITALOPRAM; DESIPRAMINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; MIRTAZAPINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; BRAIN DISEASE; BRAIN DYSFUNCTION; CINGULATE GYRUS; CLINICAL STUDY; CORRELATIONAL STUDY; DEPRESSION; DIAGNOSTIC IMAGING; HIPPOCAMPUS; HUMAN; HYPOTHESIS; IDIOPATHIC DISEASE; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OPEN STUDY; PARKINSON DISEASE; PRACTICE GUIDELINE; PREFRONTAL CORTEX; REVIEW; STROKE; TEMPORAL LOBE EPILEPSY; VASCULAR DISEASE; CLASSIFICATION; HISTOLOGY; HYPOTHALAMUS; MAJOR DEPRESSION; PATHOPHYSIOLOGY;

DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOTHALAMUS; NERVOUS SYSTEM DISEASES;

EID: 33646828343     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000194147.88647.7f     Document Type: Review

References (53)

1. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160:1516-1518.
2. McDonald C, Bullmore ET, Sham PC, et al. Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry 2004; 61:974-984. This article tries to clarify if the two major diagnostic categories of psychosis - schizophrenia and bipolar disorder - are distinct disease entities with specific genetic causes and neuroanatomical substrates.
3. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 2003; 4:46-50.
4. Fuchs E, Gould E. Mini-review: in vivo neurogenesis in the adult brain: regulation and functional implications. Eur J Neurosci 2000; 12:2211-2214.
5. Sapolsky RM. Glucocorticoids and hyppocampal atrophy in neuropsychiatry disorders. Arch Gen Psychiatry 2000; 57:925-935.
6. Rosoklija G, Toomayan G, Ellsi SP, et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 2000; 57:349-356.
7. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539-7547.
8. Mc Guffin P, Rijsdijk F, Andrew M, et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60:497-502.
9. Wu J, Buchsbaun MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 1999; 156:1149-1158.
10. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156:675-682.
11. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48:830-843.
12. Eliot R, Rubinsztein JS, Sahakian DJ, Dolan RJ. The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry 2002; 59:597-604.
13. Schmitz B. Depression and mania in patients with epilepsy. Epilepsia 2005; 46 (Suppl 4):45-49. This article explores the clinical manifestations of depressive and manic disorders in epilepsy and the differences from bipolar disorder.
14. Quiske A, Helmstaedter C, Lux S, et al. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000; 39:121-125.
15. Hermann BP, Seidenberg M, Haltiner A, et al. Mood state in unilateral temporal lobe epilepsy. Biol Psychiatry 1991; 30:1205-1218.
16. Schmitz EB, Moriatry J, Costa DC, et al. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy. J Neurol Neurosurg Psychiatry 1997; 62:458-463.
17. Savic I, Lindstrom P, Gulyas B, et al. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004; 62:1343-1351. The purpose of the article is testing the hypothesis that in mesial temporal lobe epilepsy (MTLE) there is involvement outside of mesial structures and that this involvement affects serotonin systems, thus suggesting a mechanism for affective symptoms in this population.
18. Chugani DC, Chugani HT. Does serotonin have trophic effects in temporal lobe epilepsy? Neurology 2003; 60:736-737.
19. Pisani F, Spina E, Oteri G. Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice. Epilepsia 1999; 40 (Suppl 10):S48-S56.
20. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 2000; 1:100-105.
21. Kuhn K-U, Quednow BB, Thiel M, et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav 2003; 4:674-679.
22. Blummer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. J Clin Psychiatry 1997; 58:3-11.
23. Goodwin GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol 1997; 11:971-975.
24. Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 2001; 71:258-261.
25. Vataja R, Pohjsvaara T, Leppavuori A, et al. Magnetic resonance imaging correlates of depression after ischemic stroke. Arch Gen Psychiatry 2001; 214:227-231.
26. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997; 54:915-922.
27. Greenwald DS, Kramer-Ginsberg E, Krishnan RR, et al. MRI signal hyperintensities in geriatric depression. Am J Psychiatry 1996; 153:1212-1215.
28. Greenwald DS, Kramer-Ginsberg E, Krishnan RR, et al. Neuroanatomic localization of magnetic resonance imaging signal hyperintensities in geriatric depression. Stroke 1998; 29:613-617.
29. Iidaka T, Nakajima T, Kauamoto K, et al. Signal hyperintensities on brain magnetic resonance imaging in elderly depressed patients. Eur Neurol 1996; 36:293-299.
30. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993; 43:1683-1689.
31. Thomas AJ, O'Brein JT, Davis S, et al. Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry 2002; 59:785-792.
32. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005; 36:1098-1103. A systematic review of randomized placebo-controlled trials of antidepressants for the treatment or prevention of depressive illness and 'abnormal mood' after stroke.
33. Jellinger KA. Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991; 14:153-197.
34. Ghazi-Noori S, Chung TH, Deane KHO, et al. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003465.
35. Lemke MR, Fuchs G, Gemende I, et al. Depression and Parkinson's disease. J Neurol 2004; 251 (Suppl 6):24-27. A general description of clinical symptoms and treatment of depression in Parkinson's disease.
36. Högl B, Peralta C, Wetter TC, et al. Effect of sleep deprivation of motor performance in patients with Parkinson's disease. Move Disord 2001; 16:616-621.
37. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:1171-1174. An article focused on the study of the efficacy of 15 Hz repetitive transcranial magnetic stimulation (rTMS) in treating depression in patients with Parkinson's disease.
38. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multi-centre prospective randomized study. Eur J Neurol 2003; 10:399-406.
39. Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:834-839. This study evaluated the cognitive, mood, and behavioural effects of bilateral subthalamic nucleus deep brain stimulation.
40. Zorzon M, De Masi R, Nasuelli D, et al. Depression and anxiety in multiple sclerosis: a clinical and MRI study in 95 patients. J Neurol 2001; 248:416-421.
41. Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62:586-590. The authors made an assessment of the association between major depression and structural brain abnormalities in patients with multiple sclerosis.
42. Foley FW, Traugott U, La Rocca NG, et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol 1992; 49:238-244.
43. Seidel A, Arolt V, Hunstiger M, et al. Cytokine production and serum proteins in depression. Scand J Immunol 1995; 41:534-538.
44. Mohr DC, Goodkin DE, Islar J, et al. Treatment of depression is associated with suppression of non specific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 2001; 58:1081-1086.
45. Loftis MJ, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82:175-190.
46. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990; 147:1493-1497.
47. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001; 69:942-949.
48. Browning WN. Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine. Am J Psychiatry 1990; 147:1089.
49. Benedetti F, Campori E, Colombo C, Smeraldi E. Fluvoxamine treatment of major depression associated with multiple sclerosis. Neuropsychiatry Clin Neurosci 2004; 16:364-366. In this article the antidepressant efficacy and the tolerability of fluvoxamine was examined in 43 interferon b-1b treated patients affected by major depression associated with MS.
50. Sharre DW, Davis RA, Warner JL. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11:687-691.
51. Steinberg M, Munro CA, Quincy S, et al. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. Int J Geriatr Psychiatry 2004; 19:144-150.
52. Finkel SI, Mintzer JE, Dysken M, et al. A randomised, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioural manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19:9-18.
53. Munro CA, Brandt J, Sheppard JM, et al. Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 2004; 12:491-498. The authors assessed the cognitive effects of depression treatment with sertraline in patients with Alzheimer's disease and major depression.